Actively Recruiting
Phase II Study of SHR-2173 Injection for Treating Primary IgA Nephropathy Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Effectiveness and Safety
Led by Guangdong Hengrui Pharmaceutical Co., Ltd · Updated on 2026-05-13
84
Participants Needed
2
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of SHR-2173 injection in adults with Primary IgA Nephropathy, a kidney condition. This randomized, double-blind, placebo-controlled Phase II trial will include about 84 participants and aims to measure changes in urine protein levels and kidney function. The study includes a screening period, a run-in period, a 48-week treatment phase, and a 12-week follow-up. Participants will be randomly assigned to receive one of three different doses of SHR-2173 injection or a placebo. The treatment is administered by injection during the 48-week double-blind phase. After completing treatment, participants will be monitored for an additional 12 weeks to assess safety and ongoing effects. Throughout the study, participants will undergo evaluations including urine tests to measure protein levels, kidney function tests such as estimated glomerular filtration rate, and assessments of hematuria and serum creatinine. Quality of life will also be assessed using the Kidney Disease Quality of Life Short Form. Researchers will monitor participants regularly during treatment and follow-up to track changes and any side effects over the total study duration.
CONDITIONS
Brief Title
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
Research Team
K
Kunming Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here